Recent developments in the treatment of sepsis

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2003-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.12.2.139PMID 12556210
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Annals of Internal Medicine Treatment of Septic Shock with Human Monoclonal Antibody HA-1 A A Randomized , Double-Blind , Placebo-Controlled Trial

  2009cited by this paper
• Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock*

  2004cited by this paper
• Dexamethasone in adults with bacterial meningitis.

  2003cited by this paper
• A pilot study of coupled plasma filtration with adsorption in septic shock*

  2002cited by this paper
• Depletion of neurohypophyseal content of vasopressin in septic shock.

  2002cited by this paper
• Intravenous immunoglobulin for treating sepsis and septic shock.

  2002cited by this paper
• Beneficial Effects of Short-term Vasopressin Infusion during Severe Septic Shock

  2002cited by this paper
• Dexamethasone in adults with bacterial meningitis.

  2002cited by this paper
• C1-inhibitor in patients with severe sepsis and septic shock: Beneficial effect on renal dysfunction

  2002cited by this paper
• Terlipressin for norepinephrine-resistant septic shock.

  2002cited by this paper
• A phase II randomized, controlled trial of continuous hemofiltration in sepsis

  2002cited by this paper
• The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis [ISRCTN28863830]

  2002cited by this paper
• The Modulation of Hepatic Injury and Heat Shock Expression by Inhibition of Inducible Nitric Oxide Synthase After Hemorrhagic Shock

  2002cited by this paper
• Soluble L-selectin attenuates tumor necrosis factor-&agr;-mediated leukocyte adherence and vascular permeability: A protective role for elevated soluble L-selectin in sepsis*

  2002cited by this paper
• Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis*

  2002cited by this paper
• Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis.

  2002cited by this paper
• Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

  2002cited by this paper
• Procalcitonin: a marker to clearly differentiate systemic inflammatory response syndrome and sepsis in the critically ill patient?

  2002cited by this paper
• Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study

  2001influential reference
• Role of C5a in Multiorgan Failure During Sepsis1

  2001cited by this paper
• Newly Developed Immobilized Polymyxin B Fibers Improve the Survival of Patients with Sepsis

  2001cited by this paper
• ONO-1714, a new inducible nitric oxide synthase inhibitor, attenuates diaphragmatic dysfunction associated with cerulein-induced pancreatitis in rats

  2001cited by this paper
• Scavenging nitric oxide reduces hepatocellular injury after endotoxin challenge.

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• High-volume haemofiltration in human septic shock

  2001cited by this paper
• Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis.

  2001cited by this paper
• Protective effects of anti‐C5a peptide antibodies in experimental sepsis

  2001cited by this paper
• Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock

  2001cited by this paper
• HMGB1 as a late mediator of lethal systemic inflammation.

  2001cited by this paper
• Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis.

  2001cited by this paper
• Filgrastim in patients with pneumonia and severe sepsis or septic shock.

  2001cited by this paper
• High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

  2001cited by this paper
• The Effects of Vasopressin on Systemic Hemodynamics in Catecholamine-Resistant Septic and Postcardiotomy Shock: A Retrospective Analysis

  2001cited by this paper
• A new endotoxin adsorber: first clinical application.

  2001cited by this paper
• Does the activation of poly (ADP-ribose) synthetase mediate tissue injury in the sepsis induced by cecal ligation and puncture?

  2001cited by this paper
• Effects of continuous haemofiltration vs intermittent haemodialysis on systemic haemodynamics and splanchnic regional perfusion in septic shock patients: a prospective, randomized clinical trial.

  2001cited by this paper
• Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial.

  2001cited by this paper
• Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis

  2001cited by this paper
• Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients

  2001cited by this paper
• Effects of nicotinamide, an inhibitor of PARS activity, on gut and liver O2 exchange and energy metabolism during hyperdynamic porcine endotoxemia

  2001cited by this paper
• IC14, an Anti-CD14 Antibody, Inhibits Endotoxin-Mediated Symptoms and Inflammatory Responses in Humans1

  2001cited by this paper
• Soluble L-selectin at levels present in septic patients diminishes leukocyte-endothelial cell interactions in mice in vivo: A mechanism for decreased leukocyte delivery to remote sites in sepsis

  2001cited by this paper
• Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

  2001cited by this paper
• The effect of C1-esterase inhibitor in definite and suspected streptococcal toxic shock syndrome. Report of seven patients

  2000cited by this paper
• A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis

  2000cited by this paper
• Plasma granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor levels in critical illness including sepsis and septic shock: Relation to disease severity, multiple organ dysfunction, and mortality

  2000cited by this paper
• Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs

  2000cited by this paper
• E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators.

  2000cited by this paper
• Evaluation of Heparin Immobilized Chitosan-Peg Microbeads for Charcoal Encapsulation and Endotoxin Removal

  2000cited by this paper
• Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte

  2000cited by this paper
• Adsorption of microorganism components by lixelle beads.

  2000cited by this paper
• Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group.

  2000cited by this paper
• Effect of hydrocortisone on phenylephrine– mean arterial pressure dose‐response relationship in septic shock

  2000cited by this paper
• Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group.

  2000cited by this paper
• Protection from septic shock by neutralization of macrophage migration inhibitory factor

  2000cited by this paper
• A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia.

  2000cited by this paper
• Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia.

  2000cited by this paper
• Lepirudin blunts endotoxin-induced coagulation activation.

  2000cited by this paper
• Caspases -2, -3, -6, and -9, but not caspase-1, are activated in sepsis-induced thymocyte apoptosis.

  2000cited by this paper
• Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis

  2000cited by this paper
• A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia

  2000cited by this paper
• Adsorption of endotoxin on glass in the presence of rhIL-11.

  2000cited by this paper
• Polymyxin B binds to anandamide and inhibits its cytotoxic effect

  2000cited by this paper
• Anti-L-selectin antibody treatment of hemorrhagic-traumatic shock in baboons.

  1999cited by this paper
• A novel nitric oxide scavenger decreases liver injury and improves survival after hemorrhagic shock.

  1999cited by this paper
• Cytokine removal during continuous hemofiltration in septic patients.

  1999cited by this paper
• Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group.

  1999cited by this paper
• Low-dose vasopressin in the treatment of vasodilatory septic shock.

  1999cited by this paper
• Beneficial effects of mercaptoethylguanidine, an inhibitor of the inducible isoform of nitric oxide synthase and a scavenger of peroxynitrite, in a porcine model of delayed hemorrhagic shock.

  1999cited by this paper
• An enzyme immunoassay to determine the levels of specific antibodies toward bacterial surface antigens in human immunoglobulin preparations and blood serum.

  1999cited by this paper
• Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM-1 pathways.

  1999cited by this paper
• Diaspirin Cross-Linked Hemoglobin (DCLHb) in the Treatment of Severe Traumatic Hemorrhagic Shock: A Randomized Controlled Efficacy Trial

  1999cited by this paper
• Neuroprotection by a caspase inhibitor in acute bacterial meningitis

  1999cited by this paper
• Toll-like Receptor-4 Mediates Lipopolysaccharide-induced Signal Transduction*

  1999cited by this paper
• Use of adsorptive mechanisms in continuous renal replacement therapies in the critically ill.

  1999cited by this paper
• PHOSPHOLIPID RICH EMULSION IMPROVED SURVIVAL AND CARDIOVASCULAR STATUS IN PORCINE SEPTIC SHOCK IN A DOSE-DEPENDENT MANNER

  1999cited by this paper
• Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor 4 and β-thromboglobulin

  1999cited by this paper
• Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial.

  1999cited by this paper
• HYDROCORTISONE REVERSES REFRACTORY SEPTIC SHOCK

  1999cited by this paper
• Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.

  1999cited by this paper
• Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

  1999cited by this paper
• HMG-1 as a late mediator of endotoxin lethality in mice.

  1999cited by this paper
• Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: a placebo-controlled, double-blind trial.

  1999cited by this paper
• Pentoxifylline improves bacterial clearance during hemorrhage and endotoxemia.

  1999cited by this paper
• Effect of the administration of recombinant hirudin and/or tissue‐plasminogen activator (t‐PA) on endotoxin‐induced disseminated intravascular coagulation model in rabbits

  1999cited by this paper
• Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction.

  1999cited by this paper
• Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis.

  1999cited by this paper
• Protective effects of C5a blockade in sepsis

  1999cited by this paper
• Protective effect of poly(ADP-ribose) synthetase inhibition on multiple organ failure after zymosan-induced peritonitis in the rat.

  1999cited by this paper
• Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve.

  1998cited by this paper
• Effects of hemoperfusion with polymyxin B-immobilized fibre on serum neopterin and soluble interleukin-2 receptor concentrations in patients with septic shock.

  1998cited by this paper
• CONTINUOUS INFUSION OF PYRIDOXALATED HEMOGLOBIN POLYOXYETHYLENE CONJUGATE IN HYPERDYNAMIC SEPTIC SHEEP

  1998cited by this paper
• Effect of pentoxifylline on cytokine patterns in the therapy of complicated Plasmodium falciparum malaria.

  1998cited by this paper
• Diffusive vs. convective therapy: effects on mediators of inflammation in patient with severe systemic inflammatory response syndrome.

  1998cited by this paper
• Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study.

  1998cited by this paper
• Effects of trauma and sepsis on soluble L-selectin and cell surface expression of L-selectin and CD11b.

  1998cited by this paper
• Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.

  1998cited by this paper
• Vasopressin Deficiency Contributes to the Vasodilation of Septic Shock

  1998cited by this paper
• Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.

  1998cited by this paper
• Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.

  1998cited by this paper

• Effect of omiganan on colonic anastomosis healing in a rat model of peritonitis.

  2017cites this paper
• 간이식 후 초기 균 배양 양성결과가 단기 간이식 성적에 미치는 영향

  2011cites this paper
• Impact of Early Positive Culture Results on the Short-term Outcomes of Liver Transplants

  2011cites this paper
• S-thanatin enhances the efficacy of tigecycline in an experimental rat model of polymicrobial peritonitis.

  2010cites this paper
• Effect of anti-TNF therapy on T cell activation and effector functions in patients with chronic inflammatory diseases

  2009cites this paper
• Immunomodulatory ellagitannin chemistry

  2009cites this paper
• Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.

  2007cites this paper
• Interaction of Antimicrobial Peptide Temporin L with Lipopolysaccharide In Vitro and in Experimental Rat Models of Septic Shock Caused by Gram-Negative Bacteria

  2006cites this paper
• Inhibition by nitric oxide of cytochrome P450 4A activity contributes to endotoxin-induced hypotension in rats.

  2006cites this paper
• LL-37 Protects Rats against Lethal Sepsis Caused by Gram-Negative Bacteria

  2006cites this paper
• The response of human endothelial cell cultures to mediators of sepsis : modulation of macromolecular permeability and adhesion molecule expression

  2006cites this paper
• Recent progress in ellagitannin chemistry.

  2005cites this paper
• Extracorporeal Blood Treatment (EBT) Methods in SIRS/Sepsis

  2005cites this paper
• Effects of pexiganan alone and combined with betalactams in experimental endotoxic shock.

  2005cites this paper
• The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

  2005cites this paper
• Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis.

  2005cites this paper
• Protective Role of Angiopoietin-1 in Endotoxic Shock

  2005cites this paper
• The Role of the Vascular Factor in the Reorganization of Water Metabolism in Denervated Liver after Bacterial Endotoxin Poisoning

  2005cites this paper
• Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock.

  2004cites this paper
• New markers of sepsis using proteome analysis

  2004cites this paper
• Acute Dialysis Quality Initiative 3 rd International Consensus Conference Workgroup 1 Hemofiltration and Hemoperfusion in Sepsis and Septic Shock

  2004cites this paper
• Use of Drotrecogin Alfa (Activated) in Bariatric Surgery Patients with Severe Sepsis Syndrome: Experience in an Urban Community Teaching Hospital

  2004cites this paper
• Therapeutic efficacy of the magainin analogue MSI-78 in different intra-abdominal sepsis rat models.

  2004cites this paper
• Pentoxyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis.

  2004cites this paper
• Modulation of Adhesion Molecule Expression on Endothelial Cells after Induction by Lipopolysaccharide‐Stimulated Whole Blood

  2004cites this paper
• [Regulation of NF-kappaB transcription factor. A molecular mediator in inflammatory process].

  2004cites this paper
• Antiendotoxin activity of protegrin analog IB-367 alone or in combination with piperacillin in different animal models of septic shock.

  2003cites this paper
• Association of Proinflammatory Molecules with Apoptotic Markers and Survival in Critically Ill Multiple Organ Dysfunction Patients

  2003cites this paper
• The mechanism of Polydatin in shock treatment

  2003cites this paper
• Simultaneous activation of apoptosis and inflammation in pathogenesis of septic shock: a hypothesis 1

  2003cites this paper